摘要
精神分裂症是一组病因未明的重性精神疾病,全球患病率1%,具有患病率高、致残率高和社会负担沉重等特点。目前临床上使用的抗精神病药物能够很好的控制阳性症状,但是患者的阴性症状和认知功能缺损仍未得到有效的治疗。目前普遍认为,精神分裂症患者N-甲基-D-天冬氨酸受体功能低下是阴性症状和认知功能缺损的主要原因。由此,谷氨酸受体也逐渐成为新一代抗精神病药物研发的关键靶点。本文综述了近年来调节谷氨酸受体相关药物治疗精神分裂症的成功和失败之处,以期为对今后临床药物应用以及研究方向能有所启发。
Schizophrenia is a group of serious mental diseases without specific causes,with a high prevalence rate,high disability rate and a heavy social burden.The global prevalence of schizophrenia is 1%.At present,antipsychotic drugs can well control the positive symptoms,but the negative symptoms and cognitive impairment of patients have not been effectively treated.Currently,it is generally believed that the defect of N-methyl D-aspartate receptor is the main cause of negative symptoms and cognitive impairment in patients with schizophrenia.Therefore,glutamate receptor has gradually become a key target for the development of a new generation of antipsychotic drugs.In this paper,we will summarize the progress of glutamate receptor-related drugs for schizophrenia in recent years in order to provide some suggestions for future clinic and researches in this field.
作者
王颖怡
吕钦谕
陆燕华
易正辉
WANG Yingyi;LYU Qinyu;LU Yanhua;YI Zhenghui(General Psychiatry,Shanghai Mental Health Center,School of Medicine,Shanghai Jiao Tong University,Shanghai 201108,China)
出处
《中国医药导报》
CAS
2019年第22期42-45,65,共5页
China Medical Herald
基金
国家自然科学基金面上项目(81671326)
上海市综合医院中西医结合专项(ZHYY-ZXYJHZX-2-201708)
上海市精神卫生中心院级课题项目(2017-YJ-01、2015-YJGJ-03)
